Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oncaspar roll-over study in pediatric ALL
NCT04956666Phase 2Completed
- Sponsor
- Servier
- Start
- Jun 2021
- Primary completion
- Jan 2023
- Modality
- Therapeutic Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pegaspargase in acute lymphoblastic leukemia (ALL), sponsored by Servier. Primary endpoint: Adverse Events at 19 months. Started Jun 2021; status: completed.
02
Drugs
pegaspargase
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT04956666.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04956666.